# Sera Prognostics (SERA) Stock Price, News & Catalysts
Canonical URL: https://biopharmsignal.com/company/SERA
## Company Profile
- Ticker: SERA
- Exchange: NASDAQ
- Sector: MedTech
- Location: United States
- Tags: Diagnostics, Women's Health
## Stock Data
- Close: 1.98 USD
- Market cap: 79883799 USD
- Last updated: 2026-09-03
## Business Overview
### Precision Pregnancy Diagnostics
Sera Prognostics develops blood-based biomarker tests intended to identify pregnancy risks before complications become clinically apparent. Its objective is to support earlier, personalized intervention for mothers and newborns.
### PreTRM Test
The PreTRM Test measures maternal blood proteins during weeks 18 through 20 of pregnancy to estimate an individual's risk of spontaneous preterm birth. Physicians can use the result to guide risk-reduction care for higher-risk pregnancies.
### Clinical Evidence Base
The test is supported by validation studies and the PRIME randomized controlled trial, which evaluates the clinical and economic effects of PreTRM-guided care. Sera continues to publish subgroup and health-economic analyses from this evidence base.
### Payer-Led Adoption Model
Sera works with health plans and state-based programs to implement testing across covered populations. This model combines payer contracting, provider education, reimbursement readiness, and integration into prenatal-care pathways.
### Pregnancy Complications Pipeline
Beyond spontaneous preterm birth, Sera is developing diagnostic approaches for other pregnancy complications using its proteomic biomarker platform.
## Why The Stock Is Moving

As of Sep 3, 2026, SERA closed down 1.49% at $1.98. No new same-company headline was identified in the current news window.

## Future Catalysts

- Completion of the European CE-mark submission for the PreTRM Test in the fourth quarter of 2026.

## Recent News
- 2026-08-25 12:00 EST — [1 in 10 U.S. Babies Are Born Too Early. A Leading OB-GYN Says Most Mothers Can Learn Their Risk by Week 21, and Do Something About It](https://biopharmsignal.com/news/SERA/1-in-10-u-s-babies-are-born-too-early-a-leading-ob-gyn-says-most-mothers-can-lea-3ce74ffe) — Source: Sera Prognostics
- 2026-08-19 20:30 EST — [SERA PROGNOSTICS APPOINTS SCOTT GLEASON CHIEF FINANCIAL OFFICER](https://biopharmsignal.com/news/SERA/sera-prognostics-appoints-scott-gleason-chief-financial-officer-4701ba99) — Source: Sera Prognostics
- 2026-08-12 20:05 EST — [SERA PROGNOSTICS REPORTS SECOND QUARTER 2026 FINANCIAL RESULTS](https://biopharmsignal.com/news/SERA/sera-prognostics-reports-second-quarter-2026-financial-results-4e6a97b0) — Source: Sera Prognostics
- 2026-07-29 20:05 EST — [SERA PROGNOSTICS ANNOUNCES CONFERENCE CALL AND WEBCAST OF SECOND QUARTER FISCAL YEAR 2026 FINANCIAL RESULTS ON AUGUST 12, 2026](https://biopharmsignal.com/news/SERA/sera-prognostics-announces-conference-call-and-webcast-of-second-quarter-fiscal--2a2c0c5a) — Source: Sera Prognostics
- 2026-07-09 20:05 EST — [PRIME SUBGROUP ANALYSIS DEMONSTRATES 22% REDUCTION IN NICU ADMISSIONS IN FIRST-TIME PREGNANCIES USING PreTRM® Test-GUIDED CARE](https://biopharmsignal.com/news/SERA/prime-subgroup-analysis-demonstrates-22-reduction-in-nicu-admissions-in-first-ti-1eec527c) — Source: Sera Prognostics